ReviewFrontiers in human neuroscience2014
Neurorestorative therapy for stroke.
Review in Frontiers in human neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 1 synthesis or guideline pooled it, 171 citations in OpenAlex.
- The cellular model for Alzheimer's disease research: PC12 cells.Frontiers in molecular neuroscience · 2022Pooled it
- Trial
- Exosomal Cargoes Derived from Neural Stem Cell: A New Strategy of Parkinson's Disease Treatment.Molecular neurobiology · 2026Review
- Re-Examination and Extension of Manual Dexterity Behavioral Data in M1 Lesioned Adult Macaque Monkeys: A Survey of Therapies Induced Enhancement of Functional Recovery.Neuroscience insights · 2026Article
- Angiogenesis and Hypoxia Biomarkers Are Dysregulated in Progressive Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Confirmation of the Enhancement Effect of ANCE Treatment on Functional Recovery of Manual Dexterity From Primary Motor Cortex (M1) Lesion in Adult Macaque Monkeys.Brain and behavior · 2025Article
- Therapeutic Potential of Mesenchymal Stem Cells in Stroke Treatment.Biomolecules · 2025Review
- Abolishing UCHL1's hydrolase activity exacerbates ischemia-induced axonal injury and functional deficits in mice.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024Article
- Umbilical cord blood derived cell expansion: a potential neuroprotective therapy.Stem cell research & therapy · 2024Review
- Effect of smoking status on clinical outcomes after reperfusion therapy for acute ischemic stroke.Scientific reports · 2024Article
- Distance from main arteries influences microstructural and functional brain tissue characteristics.NeuroImage · 2024Article
- The potential of a combined cell-based therapy and rehabilitation approach for stroke recovery.Neuroprotection (Chichester, England) · 2023Review
- Evaluation of prophylactic efficacy of sodium thiosulfate in combating I/R injury in rat brain: exploring its efficiency further in vascular calcified brain slice model.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Neural stem cell-derived exosomes and regeneration: cell-free therapeutic strategies for traumatic brain injury.Stem cell research & therapy · 2023Review
- Circulating extracellular vesicles promote recovery in a preclinical model of intracerebral hemorrhage.Molecular therapy. Nucleic acids · 2023Article
- A Comparative Study on the Neuroprotective Effect of Geopung-Chunghyuldan on In Vitro Oxygen-Glucose Deprivation and In Vivo Permanent Middle Cerebral Artery Occlusion Models.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Neuroprotective Effects of Geopung-Chunghyuldan Based on Its Salvianolic Acid B Content Using an In Vivo Stroke Model.Current issues in molecular biology · 2023Article
- Functional brain networks in the evaluation of patients with neurodegenerative disorders.Nature reviews. Neurology · 2023Review
- The Role of Nrf2 in Relieving Cerebral Ischemia-Reperfusion Injury.Current neuropharmacology · 2023Review
- Astrocytes in stroke-induced neurodegeneration: a timeline.Frontiers in molecular medicine · 2023Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Ischemic stroke is responsible for many deaths and long-term disability world wide. Development of effective therapy has been the target of intense research. Accumulating preclinical literature has shown that substantial functional improvement after stroke can be achieved using subacutely administered cell-based and pharmacological therapies. This review will discuss some of the latest findings on bone marrow-derived mesenchymal stem cells (BMSCs), human umbilical cord blood cells, and off-label use of some pharmacological agents, to promote recovery processes in the sub-acute and chronic phases following stroke. This review paper also focuses on molecular mechanisms underlying the cell-based and pharmacological restorative processes, which enhance angiogenesis, arteriogenesis, neurogenesis, and white matter remodeling following cerebral ischemia as well as an analysis of the interaction/coupling among these restorative events. In addition, the role of microRNAs mediating the intercellular communication between exogenously administered cells and parenchymal cells, and their effects on the regulation of angiogenesis and neuronal progenitor cell proliferation and differentiation, and brain plasticity after stroke are described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.